stem-cell-congress-cardiology-2018-posters

Biomedical Research

Volume 29

Page 52

Note:

allied

academies

CARDIOLOGY AND CARDIOVASCULAR MEDICINE

STEM CELLS AND REGENERATIVE MEDICINE

International Conference on

J u n e 1 8 - 1 9 , 2 0 1 8 | O s a k a , J a p a n

Joint Event on

CLINICAL APPLICATION OF AUTOLOGOUS WHOLE BONE

MARROW STEM CELL TRANSPLANTATION FOR CRITICAL

LIMB ISCHEMIA WITH BUERGER’S DISEASE

Dong-ik Kim

Samsung Medical Centre, South Korea

oreaOur goal was to evaluate early results of the clinical application of autologous whole bonemarrow stemcell transplantation

(AWBMSCT) for critical limb ischemia (CLI) in patients with Buerger’s disease. We retrospectively analyzed the data of 58

limbs of 37 patients (mean age, 43.0 years; range, 28-63 years; male, 91.9%) with Buerger’s disease with CLI who were treated

with AWBMSCT. We analyzed Rutherford category, pain score, pain-free walking time (PFWT), total walking time (TWT), ankle

brachial pressure index (ABPI), and toe brachial pressure index (TBPI), and investigated wound healing and occurrence of

unplanned amputations. The mean follow-up duration was 11.9±7.2 months (range, 0.9-23.9 months) and 100%, 72.4%, and

74.1% of patients were available to follow-up 1, 3 and 6 months after AWBMST, respectively. At 6 months, patients demonstrated

significant improvements in Rutherford category (P<0.0001), pain score (P<0.0001), PFWT (P<0.0001) and TBPI (P<0.0001).

ABPI was increased compared to baseline, but the difference was not significant. A total of 76.5% ischemic wounds achieved

complete or improved healing. AWBMSCT is a safe and effective alternative or adjunctive treatment modality to achieve clinical

improvement in patients with CLI.

Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C2-006